This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Surging Earnings Estimates Signal Upside for Doximity (DOCS) Stock
by Zacks Equity Research
Doximity (DOCS) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Are Medical Stocks Lagging CareDx (CDNA) This Year?
by Zacks Equity Research
Here is how CareDx (CDNA) and Doximity (DOCS) have performed compared to their sector so far this year.
Doximity (DOCS) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Doximity (DOCS) delivered earnings and revenue surprises of 15.38% and 7.70%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
InnovAge Holding Corp. (INNV) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
InnovAge (INNV) delivered earnings and revenue surprises of 0% and 0.88%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Doximity (DOCS) Outperforms Broader Market: What You Need to Know
by Zacks Equity Research
Doximity (DOCS) closed at $41.88 in the latest trading session, marking a +1.11% move from the prior day.
Doximity (DOCS) Sees a More Significant Dip Than Broader Market: Some Facts to Know
by Zacks Equity Research
In the most recent trading session, Doximity (DOCS) closed at $41.42, indicating a -1.76% shift from the previous trading day.
Is Janus Henderson Small Cap Growth Alpha ETF (JSML) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for JSML
Should Janus Henderson Small Cap Growth Alpha ETF (JSML) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for JSML
Zacks Industry Outlook Highlights Elevance Health, Doximity and HealthEquity
by Zacks Equity Research
Elevance Health, Doximity and HealthEquity are part of the Zacks Industry Outlook article.
3 Medical Services Stocks to Buy to Navigate Industry Challenges
by Urmimala Biswas
The Zacks Medical - Services industry is growing on nursing care market growth and digital healthcare adoption. ELV, DOCS and HQY are set to gain the most. Healthcare staffing shortages are leading to an increase in labor wages.
Are Medical Stocks Lagging Atea Pharmaceuticals (AVIR) This Year?
by Zacks Equity Research
Here is how Atea Pharmaceuticals, Inc. (AVIR) and Doximity (DOCS) have performed compared to their sector so far this year.
Doximity (DOCS) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the closing of the recent trading day, Doximity (DOCS) stood at $42.90, denoting a +0.87% change from the preceding trading day.
Doximity (DOCS) Increases Despite Market Slip: Here's What You Need to Know
by Zacks Equity Research
Doximity (DOCS) reachead $40.88 at the closing of the latest trading day, reflecting a +0.62% change compared to its last close.
SOLV vs. DOCS: Which Stock Is the Better Value Option?
by Zacks Equity Research
SOLV vs. DOCS: Which Stock Is the Better Value Option?
LTH vs. DOCS: Which Stock Is the Better Value Option?
by Zacks Equity Research
LTH vs. DOCS: Which Stock Is the Better Value Option?
Is Janus Henderson Small Cap Growth Alpha ETF (JSML) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for JSML
Should Janus Henderson Small Cap Growth Alpha ETF (JSML) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for JSML
LTH vs. DOCS: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
LTH vs. DOCS: Which Stock Is the Better Value Option?
Doximity (DOCS) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Doximity (DOCS) delivered earnings and revenue surprises of 27.27% and 5.67%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Gear Up for Doximity (DOCS) Q1 Earnings: Wall Street Estimates for Key Metrics
by Zacks Equity Research
Beyond analysts' top -and-bottom-line estimates for Doximity (DOCS), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2024.
CareDx (CDNA) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
CareDx (CDNA) delivered earnings and revenue surprises of 292.31% and 37.32%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Why the Market Dipped But Doximity (DOCS) Gained Today
by Zacks Equity Research
Doximity (DOCS) closed the most recent trading day at $28.66, moving +1.49% from the previous trading session.
3 Medical Services Industry Stocks to Buy as Healthcare Wage Increases
by Urmimala Biswas
The Zacks Medical - Services industry is growing on nursing care market growth and digital healthcare adoption. ICLR, OGN and DOCS are set to gain the most. Healthcare staffing shortages are leading to an increase in labor wages.
Doximity (DOCS) Stock Moves -1.24%: What You Should Know
by Zacks Equity Research
In the latest trading session, Doximity (DOCS) closed at $27.88, marking a -1.24% move from the previous day.
Doximity (DOCS) Stock Moves -1.23%: What You Should Know
by Zacks Equity Research
In the closing of the recent trading day, Doximity (DOCS) stood at $28.99, denoting a -1.23% change from the preceding trading day.